Biogen/AbbVie MS Drug Zinbryta Approved; Faces Crowded Market, Liver Concerns
Executive Summary
Biogen Inc. and AbbVie Inc. may have won the FDA's approval to market Zinbryta (daclizumab) as a treatment for multiple sclerosis, but the firms are facing significant barriers in marketing the drug, which is entering an already crowded field and coming to the marketplace with a black-box warning about serious adverse liver risks, limiting its sales potential.
You may also be interested in...
Biogen, AbbVie Withdraw Struggling MS Drug Zinbryta Due To Safety Issues
Antibody was approved in the US with a liver safety warning while EU regulators recently limited the drug's use. Now, EMA has begun an urgent review of reports of inflammatory brain disorders related to Zinbryta.
Race To Build Zinbryta's MS Market Share Ahead Of Even More Competition
New multiple sclerosis drug Zinbryta adds a European approval to its regulatory status, but is targeting a market where there are already various options for treating relapsing-remitting MS patients.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.